200 cervical cancer deaths prevented by HPV vaccine in England
Women who received an HPV vaccine as young teenagers have virtually zero risk of dying from cervical cancer before the age of 30, UK researchers have calculated.
Their analysis reported in The Lancet also found that the HPV vaccine has prevented 200 deaths from cervical cancer in England so far.
The number of lives saved will grow as vaccinated generations grow older, and more people receive the vaccination, the team from Queen Mary University of London said.
The school-based HPV vaccination programme was introduced across the UK in 2008 for 12-to-13-year-old girls and was extended to eligible boys in 2019.
Related Article: Warning issued over advertising new prescription-only weight loss pill
Catch-up jabs have been available via GP practices up to the age of 25 years.
The analysis of rates of cervical cancer mortality in women in England after the national vaccination programme came in, also found no deaths from cervical cancer in women aged 20-24 years in England for the first time between 2020 and 2024.
At the point they were offered the immunisation, HPV vaccine coverage was close to 90%.
Professor Peter Sasieni, professor of cancer epidemiology at Queen Mary University of London said: ‘This is the first study to highlight the impact of HPV vaccination on cervical cancer mortality.
‘It’s amazing news that no women aged between 20-24 died from cervical cancer in the whole of England between 2020 and 2024.
He added the findings show ‘just how vital it is to keep HPV vaccination levels high so more people are protected’.
Currently uptake of the vaccine remains below the level needed to eliminate cervical at just 76–86% of girls and 71-80% of boys by the age of 15 years, with even lower uptake rates in more deprived areas.
Related Article: Carers of people with dementia report reaching ‘breaking point’
Michelle Mitchell, chief executive of Cancer Research UK, said: ‘This is an incredible milestone and major progress in our mission to beat cancer.
‘We know the HPV vaccine is extremely effective at stopping cervical cancer before it starts and for the first time, these findings show it is saving lives – a powerful example of what’s possible when science is backed by strong public health programmes.
But she added with uptake having dropped, the progress made was at risk.
‘It’s essential that the UK Government and health systems urgently address this with targeted action to reach communities where uptake is the lowest.’
Last year, the NHS in England changed cervical cancer screening intervals from three to five years for women aged 25 to 49 years who have a negative HPV test.
Related Article: Rheumatoid arthritis patient trial backs up vaccination advantages of methotrexate delay
The NHS has pledged to eliminate cervical cancer by 2040 by making it ‘as easy as possible’ for people to receive a HPV vaccination and increasing cervical screening uptake.
A version of this article was first published by our sister title Pulse
See how our symptom tool can help you make better sense of patient presentations
Click here to search a symptom